Items in cart [0] Questions? Call 888-624-8373

PAPERBACK + PDF your price: $37.50 add to cart PAPERBACK list:$32.00 Web:$28.80 add to cart PDF BOOK your price: $24.50 add to cart PDF CHAPTERS your price: $4.50 select Rights & Permissions Free Resources PDF EXECUTIVE SUMMARY Display this book on your site! Related Titles The Threat of Pandemic Influenza: Are We Ready? Workshop Summary Globalization, Biosecurity, and the Future of the Life Sciences Other Related Titles Giving Full Measure to Countermeasures: Addressing Problems in the DoD Program to Develop Medical Countermeasures Against Biological Warfare Agents (2004) Medical Follow-Up Agency (MFUA) Institute of Medicine (IOM) Board on Life Sciences (BLS) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 127   E-mail  Facebook  Digg  Stumble  Twitter More Page 127 Front Matter (R1-R20) Executive Summary (1-18) 1 Ending Half-Measures for Countermeasures: The Challenge and Major Recommendations (19-43) 2 Organizing Research and Development for Medical Countermeasures to Accomplish Essential Functions (44-72) 3 Challenges in the Research and Development of Medical Countermeasures Against Biological Warfare Agents (73-102) Appendix A: Background: The Current Dod Medical Biowarfare Countermeasures Program (103-116) Appendix B: Agendas for Information-Gathering Meetings (117-126) Appendix C: Acknowledgements (127-130) Appendix D: Biographical Sketches (131-140)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 127
APPENDIX C Acknowledgments T he committee is grateful to the following individuals who provided information and assistance to the study through presentations or par- ticipation at meetings and workshops, informal meetings, or other means. Affiliations listed are those at the time of the individual's first con- tact with the committee. Vivian Albert, Ph.D., Vice President, Preclinical Research and Development, Human Genome Sciences Penrose (Parney) Albright, Ph.D., Senior Advisor, Science and Technology Directorate, Department of Homeland Security Maria Bernwinkler, Director, Clinical Research, PPD LTC Robert Borowski, Ph.D., Senior Medical Advisor, Office of the Deputy Assistant to the Secretary of Defense for Chemical and Biological Defense COL W. Neal Burnette, Ph.D., Assistant Joint Program Executive Officer, Medical Systems, Joint Program Executive Office for Chemical and Biological Defense Programs John Carney, Ph.D., Unconventional Pathogen Countermeasures Program, Defense Advanced Research Projects Agency Salvatore Cirone, D.V.M., M.P.V.M., Program Director, Health Science Policy, Force Health Protection and Readiness, Office of the Assistant Secretary of Defense (Health Affairs) LTC Edward Clayson, Ph.D., Chemical Biological Medical Systems, Joint Program Executive Office for Chemical and Biological Defense 127

OCR for page 128
128 GIVING FULL MEASURE TO COUNTERMEASURES COL David Danley, Ph.D., Director, Chemical Biological Medical Systems, Joint Program Executive Office for Chemical and Biological Defense David Edman, Ph.D., Chemical Biological Medical Systems, Joint Program Executive Office for Chemical and Biological Defense William Egan, Ph.D., Deputy Director, Office of Vaccines Research and Review, Food and Drug Administration Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases Richard Fieldhouse, Professional Staff Member, Senate Armed Services Committee MAJ Ronald Fizer, Joint Requirements Integrator, Joint Requirements Office for Chemical, Biological, Radiological, and Nuclear Defense Joan Fusco, Ph.D., Vice President, Technical Affairs, Baxter Vaccines Karen Goldenthal, M.D., Director, Division of Vaccines and Related Products Applications, Center for Biologics Evaluation and Research, Food and Drug Administration Jesse Goodman, M.D., M.P.H., Director, Center for Biologics Evaluation and Research, Food and Drug Administration Christine Grant, J.D., M.B.A., Vice President, Public Policy and Government Relations, Aventis Pasteur Carole Heilman, Ph.D., Director, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases COL Erik Henchal, Ph.D., Commander, U.S. Army Medical Research Institute of Infectious Diseases Stephen Hoffman, M.D., Chief Executive and Scientific Officer, Sanaria Inc. COL Charles Hoke, Jr., M.D., U.S. Army Medical Research and Materiel Command Terry Irgens, President, DynPort Vaccine Company LLC Leonard Izzo, Technical Director, Joint Requirements Office for Chemical, Biological, Radiological, and Nuclear Defense Virginia Johnson, Ph.D., Vice President for Regulatory Affairs, DynPort Vaccine Company LLC Anna Johnson-Winegar, Ph.D., Deputy Assistant to the Secretary of Defense for Chemical and Biological Defense Raymond Keifer, Ph.D., Senior Director Manufacturing, BioReliance Corporation Lawrence Kerr, Ph.D., Assistant Director for Homeland Security, Office of Science and Technology Policy Dale Klein, Ph.D., Assistant to the Secretary of Defense for Nuclear and Chemical and Biological Defense

OCR for page 129
APPENDIX C 129 Rudy Kuppers, Ph.D., SAIC Support Contractor, Military Infectious Diseases Research Program, U. S. Army Medical Research and Materiel Command Jeffrey Kushan, J.D., Partner, Sidley Austin Brown and Wood Michael J. Langford, D.V.M., Ph.D., Senior Vice President and Chief Scientific Officer, DynPort Vaccine Company LLC Frank Lee, Ph.D., President and CEO, engeneOS Brad Leissa, M.D., Deputy Director, Division of Counterterrorism, Center for Drug Evaluation and Research, Food and Drug Administration Stanley Lemon, M.D., Dean of Medicine and Professor, University of Texas Medical Branch, Galveston Carol Linden, Ph.D., Director, Medical Chemical and Biological Defense Research Program, U.S. Army Medical Research and Materiel Command Chuck Ludlam, J.D., Counsel, Office of Senator Joseph Lieberman MG Lester Martinez-Lopez, M.D., Commander, U.S. Army Medical Research and Materiel Command Mark B. McClellan, M.D., Ph.D., Commissioner, Food and Drug Administration John McCormick, M.D., Orphan Products Development, Food and Drug Administration Andrea Meyerhoff, M.D., Director, Counterterrorism Programs, Office of the Commissioner, Food and Drug Administration Alan B. Morrison, LL.B., Public Citizen Litigation Group Dianne Murphy, M.D., Director, Office of Counterterrorism and Pediatric Drug Development, Center for Drug Evaluation and Research, Food and Drug Administration Col Joseph Palma, M.D., M.P.H., Chief Medical Advisor, Office of the Deputy Assistant to the Secretary of Defense for Chemical and Biological Defense Dennis Panicali, Ph.D., Chief Scientific Officer, Therion Biologics COL Gerald Parker, M.S., D.V.M., Ph.D., Assistant Deputy for Research and Development, U.S. Army Medical Research and Materiel Command Vicki Pierson, Ph.D., Biodefense Projects Manager, Office of Biodefense Research Affairs, National Institute of Allergy and Infectious Diseases Rick Prouty, Medical Action Officer, Joint Requirements Office for Chemical, Biological, Radiological, and Nuclear Defense Gerald V. Quinnan, Jr., M.D., Professor and Chair of Preventive Medicine, Uniformed Services University of the Health Sciences

OCR for page 130
130 GIVING FULL MEASURE TO COUNTERMEASURES Jean Reed, Professional Staff Member, House Armed Services Committee BG Stephen Reeves, Program Executive Officer, Chemical and Biological Defense Philip Russell, M.D., Office of Emergency Preparedness Planning, Department of Health and Human Services Jerald Sadoff, M.D., Washington, DC Lynn Selfridge, Chemical Biological Medical Systems, Joint Program Executive Office for Chemical and Biological Defense Leonard Smith, Ph.D., Department of Immunology and Molecular Biology, Division of Toxicology, U.S. Army Medical Research Institute of Infectious Diseases John D. Strandberg, D.V.M., Ph.D., Director, Division of Comparative Medicine, National Center for Research Resources, National Institutes of Health COL David Vaughn, M.D., M.P.H., Research Area Director, Military Infectious Diseases Research Program, U.S. Army Medical Research and Materiel Command LTC Keith R. Vesely, D.V.M., Ph.D., Chief, Medical Science and Technology Division, Chemical and Biological Defense Directorate, Defense Threat Reduction Agency Judith Wagner, Ph.D., Scholar in Residence, Institute of Medicine Jay Winchester, Office of the Staff Judge Advocate, U.S. Army Medical Research and Materiel Command William Winkenwerder, Jr., M.D., M.B.A., Assistant Secretary of Defense for Health Affairs Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, Food and Drug Administration Peter Young, M.B.A., President and CEO, AlphaVax Philip Youngman, Ph.D., Vice President of Discovery Biology, Elitra Pharmaceuticals Kathryn Zoon, Ph.D., Director, Center for Biologics Evaluation and Research, Food and Drug Administration

Representative terms from entire chapter:

program executive